BridgeBio Pharma Pre-Tax Profit Margin 2018-2024 | BBIO

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

BridgeBio Pharma average pre-tax profit margin for 2023 was -5766.86%, a 782.17% decline from 2022.
BridgeBio Pharma average pre-tax profit margin for 2022 was -653.71%, a 28.24% increase from 2021.
BridgeBio Pharma average pre-tax profit margin for 2021 was -911.03%, a 55.85% decline from 2020.

Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

BridgeBio Pharma average pre-tax profit margin for 2023 was -5766.86%, a 782.17% decline from 2022.
BridgeBio Pharma average pre-tax profit margin for 2022 was -653.71%, a 28.24% increase from 2021.
BridgeBio Pharma average pre-tax profit margin for 2021 was -911.03%, a 55.85% decline from 2020.

Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.

Related Stocks
Company Name	Market Cap
Teva Pharmaceutical Industries (TEVA)	$20.1B
Dr Reddy's Laboratories (RDY)	$13.1B
Bausch Health Cos (BHC)	$3B
Amphastar Pharmaceuticals (AMPH)	$2.4B
Supernus Pharmaceuticals (SUPN)	$1.8B
Taysha Gene Therapies (TSHA)	$449M
Personalis (PSNL)	$315M
Assembly Biosciences (ASMB)	$117M
Acasti Pharma (ACST)	$28M
Sol-Gel Technologies (SLGL)	$20M
Evoke Pharma (EVOK)	$4M
Teligent (TLGT)	$0M